Danaher nears $10B acquisition of medical tech company Masimo, FT reports

139.93BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US2358511028
CUSIP
235851110
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
35.47
PEG Ratio
1.30
Book Value
74.81
Dividend Share
1.44
Dividend Yield
0.72%
Earnings Share
5.54
Wall Street Target Price
227.61
EPS Estimate Current Year
8.51
EPS Estimate Next Year
9.26
EPS Estimate Current Quarter
1.8433
EPS Estimate Next Quarter
2.0521
Most Recent Quarter
-
Revenue TTM
25,106,999,296
Gross Profit TTM
14,750,999,552
EBITDA
8,028,000,256
Profit Margin
15.95%
Return On Assets TTM
3.95%
Return On Equity TTM
7.61%
Revenue Per Share TTM
35.472
Qtly Revenue Growth YOY
5.50%
Diluted Eps TTM
5.54
Qtly Earnings Growth YOY
59.70%
Trailing PE
35.47
Forward PE
23
Price Sales TTM
5.5016
Price Book MRQ
2.6612
Enterprise Value Revenue
6
Enterprise Value EBITDA
21
71.01
1.62%687.76
-2.46%235.02
-1.45%266.51
-1.15%377.31
-0.98%574.26
-0.34%556.62
-0.30%138.37
-0.18%204.10
-0.13%21.55
-0.05%Curated watchlists where DHR is featured.
Danaher nears $10B acquisition of medical tech company Masimo, FT reports
Danaher closes in on nearly $10bn deal for medical device maker Masimo - Financial Times
Agilent, Danaher could be potential buyers of Qiagen - analyst
Nvidia gives up gains — plus, what's behind another rough day for Danaher
Here's why Danaher shares fell 4% on Thursday — a week after hitting record highs
Cramer says Danaher is a buy and weighs in on probes of Microsoft and Nvidia